The two-part ARC-SparX platform separates the disease recognition and killing functions of conventional cell therapies, enabling improved control of cell activity and precise targeting of antigens on diseased cells.
Arcellx invites inquiries from candidates who share the vision of developing innovative immune cell therapies.